Uniting Expertise, Amplifying Impact
Our success is fueled by strong partnerships that extend across science, healthcare, and industry.
Powering Discovery Through Partnerships
Foundational Partnerships
The University of Nevada, Reno, and the Dean Burkin Lab are critical partners and the originators of our extensive research. Strykagen serves as our exclusive research partner.
Research Collaborations
We collaborate with leading muscular dystrophy research labs at major academic institutions, including the University of Nevada, Reno, to support the development and advancement of our therapeutic pipeline.
Strategic Collaborations
We are actively collaborating with patient support organizations such as Duchenne UK and Duchenne Australia to help inform the design of our clinical trials. At the same time, we are seeking support to complete our early-stage clinical studies. Exploratory discussions are ongoing with pharmaceutical companies for potential partnerships or collaborations. We are open to licensing opportunities and have a stealth alliance for laminins in ultra-rare diseases.
Service Providers & Partners
We partner with leading service providers for specific expertise, including Celito (IT, Cybersecurity, Quality, G&A Infrastructure), Putnam Insights, and Scendea.
Patient Advocacy Partnerships
We are committed to partnering with patient advocacy groups such as Cure CMD and PPMD to keep the patient community informed and engaged throughout our development process.
Regulatory Partners
We recognize the necessity of regulatory partners to navigate the complex path to drug approval.
Potential Future Collaborations
We see strong potential for future collaborations with industry leaders in gene therapy and genetic disorders, particularly those with advanced clinical development capabilities and innovative platforms that complement our therapeutic approach.
